Aldeyra Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Aldeyra Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.00
Cost of Revenue0.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.00
Operating Expenses
Research & Development48.2229.4647.3144.9424.6844.3529.82
Selling, General & Administrative11.8913.3415.3711.289.9912.159.88
Operating Expenses60.1242.7962.6856.2232.9163.0739.70
Operating Income-60.12-42.79-62.68-56.22-36.42-63.07-39.70
Other Income/Expense
Interest Income6.197.322.350.190.290.000.95
Interest Expense-1.93-2.071.691.74-1.900.000.15
Other Income/Expense4.27-5.350.000.000.000.000.00
Income
Income Before Tax-55.85-37.54-62.02-57.78-38.03-62.14-38.89
Income Tax Expense0.000.000.000.00-0.48-1.310.00
Net Income-55.85-37.54-62.02-57.78-37.55-60.83-38.89
Net Income - Continuous Operations-55.85-37.54-62.02-57.780.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-59.87-42.53-60.07-55.77-36.07-61.77-38.68
EBIT-60.12-42.79-60.33-56.03-36.13-61.53-38.75
Depreciation & Amortization0.250.260.260.260.060.000.00
Earnings Per Share
Basic EPS-1.00-1.00-1.00-1.00-1.00--2.00
Diluted EPS-1.00-1.00-1.00-1.00-1.00-2.00-2.00
Basic Shares Outstanding59.4858.9458.4154.0433.9727.1121.69
Diluted Shares Outstanding59.4858.9458.4154.0433.9727.1521.69